HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetic Ingredient Review Report Status

This article was originally published in The Rose Sheet

Executive Summary

Chart: Data compiled by "The Rose Sheet" from information in CIR reports.

You may also be interested in...



Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024

Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.

Regulatory Acceptance Of Non-Animal Test Methods Holding Back Cosmetics Innovation

“Companies can innovate right now, and they have confidence in these tools, these [non-animal] approaches, and they feel they can put these products on the market safely,” said Erin Hill, CEO and president of the International Collaboration on Cosmetics Safety. “The holdup is that they can’t register these new products, because there’s a lack of confidence in the regulatory community.”

ICCS President Hill On Growing Regulatory Confidence In Alternative Testing Methodologies

In the year since its establishment, the International Collaboration on Cosmetics Safety has worked to engage with regulators as they build frameworks for assessing cosmetic safety without animal tests. ICCS president and CEO Erin Hill discusses current challenges and what lies ahead.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel